CatSci
Private Company
Funding information not available
Overview
CatSci is a privately held, revenue-generating contract research and development organization founded in 2011 and headquartered in Cardiff, UK. It acts as a specialized partner for biotech and pharma companies, offering integrated scientific services to accelerate the development of novel small molecule therapies and complex modalities like oligonucleotides and peptides. The company differentiates itself through a strong focus on complex chemistry, data-driven development, embedded sustainability practices, and a highly educated scientific team, with over 80% holding PhDs. Its business model is purely service-based, enabling client programs rather than developing its own therapeutic assets.
Technology Platform
Integrated drug development service platform combining deep expertise in chemistry, bioscience, and analytics with data-driven methodologies (DoE, HTE, predictive tools) and embedded green chemistry principles for small molecule and complex synthetic modalities.
Opportunities
Risk Factors
Competitive Landscape
CatSci competes in the fragmented CRO/CDMO market, facing competition from large global players (e.g., Labcorp, IQVIA, Charles River), large CDMOs with development services (e.g., Lonza, Catalent), and numerous specialized chemistry-focused CROs. Its differentiation lies in its deep focus on complex chemistry, integrated multi-disciplinary services, strong sustainability ethos, and tailored partnership model for biotechs and pharma.